Subject Index

A

ACF, 65–70, 72
ACTB, 76
 AD. *See* Alzheimer's disease
 Adipocyte
 genome-wide studies of formation and function, 239
 rosiglitazone modulation of genomic programming
 browning of human adipocytes, 241–243
 mature adipocyte studies, 240–241
 transcription factor cooperativity in adipogenesis, 239–240
 tumor necrosis factor–induced inflammation, 243–245
 African turquoise killfish
 advantages as laboratory model, 275–276
 CRISPR/Cas9 genome editing, 276, 278
 prospects for aging studies, 278
 telomerase knockout and human pathologies, 276–278
 Aging
 African turquoise killfish model. *See* African turquoise killfish
 overview of models, 275
 Ahp11, 113
 AID, 150
AID, 181
 Alzheimer's disease (AD)
 monocyte enhancer studies, 218
 yeast studies, 332
 Aneuploidy
 adoptive transfer for aneuploid hematopoietic malignancy studies, 99
 backcrossing and trisomic embryo fitness reduction, 96–98
 cancer, 300–301
 Down syndrome, hematopoiesis and mouse models, 98–99
 hematopoietic stem cells
 reconstitution for in vivo studies, 93–95
 Robertsonian chromosomes for aneuploidy generation, 95–96
 AP-1, 214, 250
 APOBEC, 119, 123, 150
 APOBEC3B, 119
APOE, 276
 Arg80, 270
ARID1A, 193
 ASF-1, 298
 ATM, 312
 ATR, 312
 ATRX, 167, 325

B

β-Catenin, epiblast competence for germ cell fate, 150

BFB cycle. *See* Breakage–fusion–bridge cycle
 BLIMP1, 152, 155
Blimp1, 147, 149–152
 BLM, 106
 BMAL1, 224–225, 228–231
 BMP4, 149–150
BRCAl, 120
BRCAl2, 120
 BRD4, 250
 BRD4, 353
 Breakage–fusion–bridge (BFB) cycle,
 dicentric chromosomal
 bridge resolution, 128–130
 Breast cancer, kataegis, 123

C

CAR, 250
 CBP, 241, 353
CCND1, 130
 Cdc5, 104
 Cdc13, 112
 Cdc28, 104
 Cdc48, telomere length regulation, 113–114
CDH1, 114
 Cdk6, expression in thymic lymphoma in p53 knockout mouse, 141–143
 C/EBP, 214
 C/EBPα, 239–241, 243, 245
 CENP-A, 297
 Chd1, 65, 68–69, 72
 Chromatin
 chromosome looping model, 47–48
 regulation within nuclear domains, 48–49
 Chromoanaysynthesis, patterns and mechanisms, 126–127
 Chromoplexy, patterns and mechanisms, 127–128
 Chromosomal rearrangements, global patterns, 120–123
 Chromothripsis, patterns and mechanisms, 125–126
 Circadian oscillators
 clock genes and synchronization in mammals, 224–225
 driven versus self-sustained oscillators, 229, 231
 liver circadian transcription. *See* Rev-erbα
 suprachiasmatic nucleus, 224–227, 231, 344–345
 systematic timing clues
 body temperature and actin dynamics, 227–229
 feeding, 226
 glucocorticoid hormones, 226–227
 CIRP, 228
 CLOCK, 224, 228–229
 CNV. *See* Copy number variation
COL1A1, 75–76

COP9, 190
 Copy number variation (CNV)
 global patterns, 120–123
 thymic lymphoma in p53 knockout mouse, 140–142
 CpG islands. *See* Epigenetics
 CREB, 224, 250
 CRISPR/Cas9
 African turquoise killfish studies, 276, 278
 functional characterization of annotated enhancers, 20
 high-throughput functional screening, 194
 mechanism of action, 305–307, 314–315
 reporter generation for transcription imaging, 5
 CRY, 224, 229–231
 CTC1, 11
 CTCF, 49, 84–89, 208–209, 353–354
Cx3cr1, 216
 Cyclin D, expression in thymic lymphoma in p53 knockout mouse, 141–143

D

DDX5, 259–262
 DENND2C, 193
DHFR, 129
Dio3, 178
Dlk1, 178
 DNA methylation. *See* Epigenetics
 dNLP, 66–67, 69
 DNMT1, 150, 158
 Dnmt1, 199
Dnmt1, 178, 181
 Dnmt3, 199
 Dnmt3a, 201
Dnmt3a, 177–178, 181
 Dnmt3b, 201
Dnmt3b, 177, 181
Dnmt3l, 177–178
 Down syndrome (DS), hematopoiesis and mouse models, 98–99
 DS. *See* Down syndrome
 DSIF, 33–34
 Dyskeratosis congenita, 312

E

Elongation, transcription
 noncoding RNA regulation, 36–38
 overview, 33–34
 Embryonic stem cell. *See* Pluripotency
 EME1, 103–105
 Enhancer
 activation, 17–18
 chromosome looping model, 47–48
 Ciona intestinalis studies of tissue specificity of developmental enhancer

Enhancer (*Continued*)

- Otx-a* enhancer optimization and
 - loss of tissue specificity, 30
- overview, 27–28
- prospects for study, 31–32
- suboptimal affinity binding sites
 - for restricted expression, 28
- suboptimal spacing of linked sites
 - in endogenous enhancer, 29–30
- trade-offs
 - binding affinities and syntax, 30–31
 - gene expression levels and specificity, 30
- cis*-acting elements, 46
- DNA variations and consequences, 22–23
- functional characterization of annotated enhancers, 20
- functional overview, 17, 342–343
- genomic methylation analysis, 203
- hypomethylation of DNA, 19–20
- identification in genome, 17–20
- macrophage-specific enhancer studies
 - active enhancers and transcription initiation, 215–216
 - clinical significance, 217–218
 - de novo/latent enhancers, 215
 - environmental signals, cell identity, and enhancer repertoire, 216–217
- epigenetics and genome-wide association studies, 217
- model for selection and activation, 214–215
- overview, 213–214
- prospects for study, 218–219
- promoter loops
 - chromatin structure probing, 209–210
 - linking and tracking of promoter communication, 46–47
- Rev-erb α circadian enhancers, 234–235
- super-enhancer, 353–354
- SV40, 45
- target gene selection for activation, 20–22

EPASI, 294

Epigenetics. *See also* Genomic imprinting; Histones

- DNA methylation
 - CpG islands at transcription start sites, 36
- dynamics in methylation
 - imprinting, 177–181
- genomic sequence analysis
 - enhancers, 203
 - imprinted methylation regions, 203
 - promoters, 202–203
- overview, 199
- techniques for study, 200–201
- traceable readout of endogenous DNA methylation state, 201–204
- genome-wide DNA demethylation
 - during germ cell development, 150–151, 178
- hepatic stellate cell epigenetic reprogramming in liver fibrosis, 250–251

- replication timing stability, 56
- reprogramming during mammalian reproductive cycle
 - induced pluripotent stem cell formation, 171
- overview, 155–156
- postfertilization, 168–170
- somatic cell nuclear transfer, 170
- TRIM28
 - functional overview, 156–158
 - genomic imprinting role, 158–159
 - retrotransposon regulation, 159–160
- ERBB2*, 128–129
- ESET*, 157, 167
- ESET*, 181
- Esrrb*, 190
- Est1*, telomerase regulation, 112–113
- Est3*, 111–112, 114
- ETS*, 28–32, 250, 318
- EZH2*, 349

F

- Fbxw*, 193
- FCS. *See* Fluorescence correlation spectroscopy
- FGF. *See* Fibroblast growth factor
- Fibroblast growth factor (FGF), 27, 30–32
- FISH. *See* Fluorescence in situ hybridization
- Fluorescence correlation spectroscopy (FCS), overview, 1–2
- Fluorescence recovery after photobleaching (FRAP)
 - nascent transcription site imaging, 4
 - overview, 1–2
- Fluorescence in situ hybridization (FISH)
 - chromosome looping model, 47–48
 - hiFISH, 74–75
 - HoxD* cluster spatial segregation imaging, 10, 12, 14
 - nascent transcription site imaging, 4
- FRAP. *See* Fluorescence recovery after photobleaching
- FXR, 250

G

- GATA, 27–30
- GATA6, 216
- GEN1, 104, 106–108
- Genomic imprinting
 - TRIM28 role, 158–159
 - knockout mouse studies of methylation imprints, 179–180
- KRAB domain zinc finger proteins, 181
- ZFP57
 - functional overview, 184
 - genomic imprinting role, 181–185, 321
- Glucocorticoid receptor (GR), 226, 243
- GR. *See* Glucocorticoid receptor
- GSK3, 193

H

- H19*, 178, 181–182
- HDAC3, 233, 237
- Heat shock response, 336–337
- Hematopoietic stem cell. *See* Aneuploidy

- Hepatic stellate cell (HSC)
 - epigenetic reprogramming in liver fibrosis, 250–251
- overview, 249
- Hi-C
 - enhancer target gene selection for activation, 21–22
- HoxD* cluster topologically associating domain visualization, 10–11
- High-throughput functional screening (HTFS)
 - CRISPR/Cas9, 194
 - in vivo, 195
 - organoids, 195
- High-throughput imaging. *See* HIPMap
- HIPMap
 - automated imaging, 75
 - chromosome break and translocation determination, 78–79
 - chromosome conformation capture data validation, 78
 - data analysis, 75–76
 - gene position
 - change detection, 76–77
 - determination, 76
 - hiFISH, 74–75
 - image analysis, 75
 - immunofluorescence combination studies, 79
 - principles, 73–74
 - prospects, 80
 - quality control
 - false FISH signal detection, 76
 - minimal sample size, 76
 - robustness of measurements, 76
 - RNA FISH coupling, 80
 - RNA interference screening, 78
 - scale-up, 77–78
 - systematic mapping of three-dimensional imaging, 78
 - versatility, 76
- Histones
 - epigenetic reprogramming during mammalian reproductive cycle
 - induced pluripotent stem cell formation, 171
 - overview, 155–156
 - postfertilization, 168–170
 - somatic cell nuclear transfer, 170
- variants
 - H1, 166–167
 - H2A, 166
 - H3, 165–166
 - heterochromatin establishment and maintenance by variants, 167–168
 - plasticity program role, 171–172
- HIV. *See* Human immunodeficiency virus
- HJURP, 297
- Holliday junction
 - dissolution, 103
 - processing defects and mitotic catastrophe, 106, 108
- resolution
 - human cell studies
 - GEN1, 106–107
 - SLX-MUS complex, 105–106
 - overview, 103–104
 - yeast studies, 104–105
- Hox*, 316
- Hoxa1*, 150

SUBJECT INDEX

359

- Hoxb1*, 150
HoxD cluster
 regulation overview, 9–10
 spatial segregation imaging, 10, 12
 stochastic optical reconstruction microscopy, 13–14
 topologically associating domains
 maximal chromatin elongation
 at boundary, 14–15
 visualization, 10–11
 HP, 157
 HSC. *See* Hepatic stellate cell
 HSF1, 228
 HTFS. *See* High-throughput functional screening
 Human immunodeficiency virus (HIV), 207
HXK1, 208
- I**
 IGF2, 158
 Ikaros, expression in thymic lymphoma
 in p53 knockout mouse,
 141–143
 Induced pluripotent stem cell (iPSC),
 epigenetic reprogramming
 in formation, 171
 INO80, 190
 Interphase
 chromosome structure and architecture,
 84–85
 interphase chromatin to prophase
 bands, 85–88
 metaphase to interphase bands, 88
 iPSC. *See* Induced pluripotent stem cell
 IRF, 214
- K**
KAP1, 181
KAP1, 282, 284–286
 Kataegis, patterns and mechanisms,
 123–125
KDM1B, 177–178
KLF4, 152
KLF11, 242–243
 KRAB domain zinc finger proteins. *See*
also TRIM28
 adult human cell expression and gene
 expression modulation,
 283–285
 embryogenesis role, 282–283
 genomic imprinting role, 181
 prospects for transposon control studies,
 285–287
 transposon early embryonic repression,
 282
- L**
LADF, 75–77, 79
 LADs. *See* Lamina-associated domains
 Lamina-associated domains (LADs),
 207–208, 210
 Lamins, 75–76
 LCR. *See* Locus control region
 Ldb1, 209
 LDTFs. *See* Lineage-determining
 transcription factors
 Li–Fraumeni syndrome, 139, 330
 Lineage-determining transcription factors
 (LDTFs), 214–215
- Lipopolysaccharide (LPS), 37
 Liver fibrosis. *See* Hepatic stellate cell
 Locus control region (LCR), 45
 LPS. *See* Lipopolysaccharide
LRK2, 333
 LXR, 214
- M**
Mcm1, 270
MDM2, 143
MED1, 241, 244
 Meiotic sex chromosome inactivation
 (MSCI), 168
 MEK, 193
 Metaphase
 metaphase to interphase bands, 88
 prophase chromatin to metaphase
 bands, 88
MIXL1, 152
MMP9, 76
Mmp9, 216
 MPE-seq, prenucleosome localization
 upstream of active
 promoters, 70–71
Mre11, 112
MRT-2, 129
MRTF, 229
 MSCI. *See* Meiotic sex chromosome
 inactivation
MUS81, 103–106
MusD, 159–160
MyoD, 250
- N**
Nanog, 190, 193
Nanog, 148, 171
NANOS3, 152
NAP1, 65–66, 68–69
NCoR, 216, 233, 237
 Neanderthals, 291–94
NELF, 33–34
Nespas, 182
NF-κB. *See* Nuclear factor-κB
Nfe2, 194
NFRKB, 190
Nobox, 194
Npl4, 113
Nr5a1, 192
Nr5a2, 192
 Nuclear factor-κB (NF-κB), 39, 214–215,
 244, 250
 Nuclear radial positioning, 207–208
 Nucleosome. *See* Prenucleosome
NuRD, 157, 181
- O**
Oct4, 190, 193
Oct4, 171
Otx-a enhancer. *See* Enhancer
- P**
 p53
 germline mutations in humans, 143
 Li–Fraumeni syndrome mutations,
 139, 330–331
 thymic lymphoma in knockout mouse
 copy number variation, 140–142,
 145
 DNA extraction and TCR-β
 sequencing, 144
 pathogenesis, 140
 western blotting, 145
 whole-exome sequencing, 140,
 144–145
 tumor mutations, 139–140, 143
 Pancreatic stellate cell (PSC)
 overview, 249–250
 transcriptional and epigenetic
 regulation of pancreatic
 tumor microenvironment,
 251–252
 Parkinson's disease (PD), yeast studies,
 332–333
PARP-1, 226
PBAF, 193
 PD. *See* Parkinson's disease
Pdrml, 147
Pdrml4, 148–151
Peg1, 181
Peg3, 181–182
Peg10, 181
PER, 224, 229–231
 PGC. *See* Primordial germ cell
PGC7, 181
PHO5, 68
PITX1, 328–329
PITX2, 329
 PIWI-interacting RNA, 302–304
PLAGL1, 182
PLK1, 105
 Pluripotency
 cell models, 189–190
 embryonic stem cell
 modeling of pluripotency, 194
 replication timing, 56
 reprogramming, 347
 experimental strategies
 overview, 129, 131
 single-cell mutations
 detection, 131–132
 sequencing, 132–133
 global patterns, 117–120
 high-throughput functional screening
 CRISPR/Cas9, 194
 in vivo, 195
 organoids, 195
 induced pluripotent stem cells and
 epigenetic reprogramming
 in formation, 171
 molecular dissection
 dissolution of pluripotency,
 192–193
 induction of pluripotency,
 190–192
 maintenance of pluripotency,
 190
 molecular networks, 193–194
 Point mutations
POLD3, 127
Pou5f1, 148
POU1F1, 192
PPARγ, 239–245
PRDM14, 190
 Prenucleosome
 discovery, 65–68
 formation, 66–68
 functions in active chromatin, 72
 localization upstream of active
 promoters, 70
 promoter association, 68
 prospects for study, 70–71
 stability, 67, 69–70

Primordial germ cell (PGC)
 chromatin remodeling during germ cell development, 151–152, 340–341
 development in mice, 147–148
 differentiation, 147
 epiblast competence for germ cell fate, 150
 genome-wide DNA demethylation during germ cell development, 150–151
 human primordial germ cell-like cell induction, 152–153
 reconstitution in culture of mouse cells
 primordial germ cell-like cell reconstitution by induced transcription factors, 149–150
 specification pathway, 149
 Promoter. *See* Enhancer; Transcription start site
 Prophase
 interphase chromatin to prophase bands, 85–88
 prophase chromatin to metaphase bands, 88
 PSC. *See* Pancreatic stellate cell
 P-TEFb, 34, 41
 PTEN, 331
 Pten, expression in thymic lymphoma in p53 knockout mouse, 141–143
Pten, 141
 PU.1, 40–41, 214–216
 PXR, 250

R

Rad50, 112
Rarb, 217
Rasgrf1, 178, 181–182
 RELA, 244
 Replication timing (RT)
 chromomeric banding patterns, 56
 chromosomal unit regulation, 56–57
 constant timing region, 54
 constitutive versus switching replication domains, 57–58
 gene expression relationship, 58–60
 genome-wide measurement, 54
 overview, 53
 replication origin identification, 54–55
 resolution of profiling data, 55–56
 stability, 56
 timing transition region, 54
 topologically associating domain formation, 57
 replication domain model, 57, 60
 Retinoic acid–related orphan receptors (RORs)
 liver circadian transcription regulation, 235–236
 ROR γ t regulation of Th17 cell differentiation, 259–261, 335
 REV-ERB α , 224
 Rev-erb α
 Bmal1/Clock feedback loop, 233
 circadian enhancers, 234–235
 clock coordination with retinoic acid–related orphan receptors, 235–236
 DNA binding, 233
 lipid metabolic gene regulation through active repression, 236
 prospects for study, 236–237

REV-ERB β , 224, 229
 RhoA, 229
 Rmrp, 260–262
 RNA polymerase II, 34–35, 38–39, 41–42, 46, 210
 Robertsonian chromosome, aneuploidy generation in hematopoietic stem cells, 95–96
 RORs. *See* Retinoic acid–related orphan receptors
 Rosiglitazone, modulation of genomic programming in adipocytes
 mature adipocyte studies, 240–241
 browning of human adipocytes, 241–243
 RT. *See* Replication timing
 RUNX, 250

S

SAA. *See* Serum amyloid A
 SCN. *See* Suprachiasmatic nucleus
 SCNT. *See* Somatic cell nuclear transfer
 SDTF, 215–216
 Serum amyloid A (SAA), regulation of Th17 cell effector responses, 258–259, 335
 SETDB1, 285
SETDB1, 181
 Sex chromosomes, 338–339
 SGBS. *See* Simpson–Golabi–Bemel syndrome
 Shh. *See* Sonic hedgehog
 SIM. *See* Structured illumination microscopy
 Simpson–Golabi–Bemel syndrome (SGBS), 243
 Single-particle tracking (SPT), overview, 2
 SIRT1, 226
SLC16A11, 293
 SLX–MUS complex, 105–106
 SLX1, 103, 105–106
 SLX4, 103, 105–106, 108
SMARCC1, 194
SMARCC2, 194
 Snai1, 193–194
 Snai2, 193–194
Snrpn, 181–182
 Somatic cell nuclear transfer (SCNT), epigenetic reprogramming, 170
 Sonic hedgehog (Shh), 31–32
SOX17, 152
 Sox2, 20, 190
Sox2, 148, 171
 SPT. *See* Single-particle tracking
 SRF, 229
 SSETDB1, 157
 Stellate ell. *See* Hepatic stellate cell; Pancreatic stellate cell
 STN1, 111
 Stochastic optical reconstruction microscopy (STORM)
HoxD cluster studies, 13–15
 telomere end studies, 312
 STORM. *See* Stochastic optical reconstruction microscopy
 Structured illumination microscopy (SIM)
 overview, 1–2
 prospects for transcription imaging, 5
 Suprachiasmatic nucleus (SCN), 224–227, 231, 344–345
 SWI/SNF, 353

T

TAD. *See* Topologically associating domain
 TBP, 36, 39, 46s
 Tbx3, 190
 TCAB1, 111–115
 Tcf3, 193
 Tcl1, 190
TCL1B, 152
TDG, 150
 TDP-43, 332–333
 Telomerase
 African turquoise killfish knockout studies, 276–278
 associated proteins, 113
 cell cycle regulation, 112, 114
 isolation from yeast, 112–113
 mass spectrometry studies of components, 111–114
 prospects for study, 114–115
 subunits, 111–112
 telomere length regulation by associated proteins
 Cdc48 complex, 113–114
 UFD4, 114
 TEN1, 111
TET1, 150–151
Tet1, 181–182
Tet3, 181
 TF. *See* Transcription factor
Tfap2c, 149–152
 TGF- β . *See* Transforming growth factor- β
 Th17 cell
 autoimmune disease therapeutic targeting, 261–262
 cytokines, 257
 functional overview, 257
 prospects for study, 262
 ROR γ t regulation of cell differentiation, 259–261
 segmented filamentous bacteria in induction, 257–258, 334–335
 serum amyloid A regulation of effector responses, 258–259, 335
 TH2, 209
 TH2A, 169–171
 TH2B, 169–171
 T-helper cell. *See* Th17 cell
 TLC1, 111–112
 TLR4, 215
 TNAP, 152
 TNF. *See* Tumor necrosis factor
 Topologically associating domain (TAD)
 chromatin structure probing, 208–209
 dynamics, 210
 enhancer target gene selection for activation, 22
HoxD cluster
 maximal chromatin elongation at boundary, 14–15
 visualization, 10–11
 overview, 308–309
 replication timing formation, 57
 replication domain model, 57, 60
 Transcription factor (TF)
 live-cell imaging of dynamics, 2–3
 single-particle tracking, 2
 Transcription network rewiring
 biological novelty generation
 gene duplication, 271–273

SUBJECT INDEX

361

- intercalation of a regulator, 271
 - constraints
 - duplicated transcription regulators, 268, 270–271
 - intersecting networks, 268
 - output preservation, 266–268
 - overview, 265–266
 - prospects for study, 273
 - Transcription start site (TSS)
 - CpG islands, 36
 - divergent promoters, 36, 39–42
 - genomic methylation analysis of promoters, 202–203
 - location of antisense start sites, 39–40
 - noncoding RNA regulation, 36, 39
 - promoter elements, 34–35
 - sequence analysis, 35
 - transcription factor interactions, 33
 - Transforming growth factor- β (TGF- β), 250, 258, 331
 - Transposon
 - adult human cell expression and gene expression modulation, 283–285
 - embryogenesis role, 282–283
 - functional overview, 281–282
 - KRAB domain zinc finger proteins
 - early embryonic repression, 282
 - prospects for transposon control studies, 285–287
 - TRIM28 in retrotransposon regulation, 159–160
 - TREX1, 126–127
 - TRF2, 126, 312
 - TRIM28
 - functional overview, 156–158
 - genomic imprinting role, 158–159
 - retrotransposon regulation, 159–160
 - Trp53, 119
 - TRRAP*, 193
 - Trt1, 115
 - TSS. *See* Transcription start site
 - Tumor necrosis factor (TNF),
 - inflammation induction in adipocytes, 243–245
- U**
- U1, 37–38
 - UCP1, 233
 - Ufd1, 113
 - UFD4, telomere length regulation, 114
 - Uhrf1*, 150
- V**
- VDR. *See* Vitamin D receptor
 - VEGF*, 76
 - Vitamin D analogs, cancer prevention studies, 252–253, 319–320
 - Vitamin D receptor (VDR), 243, 250–251, 253, 318–319
- W**
- WHOa, 193
 - WNT, epiblast competence for germ cell fate, 150
 - WNT3, 150
- X**
- XIST, 324–326
 - XPF, 105
 - Xrs2, 112
- Y**
- Yen1, 104–105
- Z**
- Zac1*, 182
 - ZFP57
 - functional overview, 184
 - genomic imprinting role, 181–185, 321
 - ZFP57*, 181–182
 - ZFP809*, 181
 - ZGA. *See* Zygote genome activation
 - ZicL, 31
 - ZNF91*, 181
 - ZNF93*, 181
 - Zygote genome activation (ZGA), 168, 170

Cold Spring Harbor Symposia on Quantitative Biology

Subject Index

Cold Spring Harb Symp Quant Biol 2015 80: 357-361

Access the most recent version at doi:[10.1101/sqb.2015.80.SI](https://doi.org/10.1101/sqb.2015.80.SI)

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>